Literature DB >> 10811670

Treatment of leptomeningeal metastases evaluated by interphase cytogenetics.

R J van Oostenbrugge1, A H Hopman, J W Arends, F C Ramaekers, A Twijnstra.   

Abstract

PURPOSE: Although cytologic examination of CSF is the primary method for the evaluation of response to therapy for leptomeningeal metastases (LMMs), the procedure's sensitivity decreases throughout the course of protracted therapy. We studied whether this response could be monitored more accurately through the detection of numerical chromosomal aberrations by interphase cytogenetics, using fluorescence in situ hybridization (FISH). PATIENTS AND METHODS: Seven patients treated for LMMs and with a known numerical aberration for chromosome 1 in their pretreatment CSF were included in this study. Up to 16 consecutive CSF samples were analyzed by means of the fluorescence in situ hybridization (FISH) technique for cells with aberrant chromosome 1 content. The results of routine cytology and FISH analyses were compared and were correlated with each patient's neurologic status.
RESULTS: Routine cytology detected malignancies in only 24 of the 76 samples, all of which were classified as chromosomally abnormal by FISH (except for two samples that could not be evaluated). Moreover, FISH demonstrated aneusomic cells in 32 additional samples, which could therefore be classified as malignant. The FISH results correlated better with patient neurologic status in that more malignant cells were detected in the CSF of neurologically deteriorating patients.
CONCLUSION: Using FISH in addition to performing routine cytologic examination of CSF led to a more accurate evaluation of response to treatment in patients treated for LMMs.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10811670     DOI: 10.1200/JCO.2000.18.10.2053

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  6 in total

1.  Changes of cerebrospinal fluid tumor marker levels may predict response to treatment and survival of carcinomatous meningitis in patients with advanced breast cancer.

Authors:  Christos Kosmas; Nicolas B Tsavaris; Georgia Soukouli; Panagiotis Gouveris; George Tsakonas; John Katselis; Heraklis Alexopoulos; Nicolas Mylonakis; Athanasios Karabelis
Journal:  Med Oncol       Date:  2005       Impact factor: 3.064

2.  Molecular or cytogenetic monitoring and preemptive therapy for central nervous system relapse of acute promyelocytic leukemia.

Authors:  Sumimasa Nagai; Yasuhito Nannya; Shunya Arai; Yumiko Yoshiki; Tsuyoshi Takahashi; Mineo Kurokawa
Journal:  Haematologica       Date:  2010-01       Impact factor: 9.941

Review 3.  Novel approaches to treating leptomeningeal metastases.

Authors:  Jai Grewal; Marlon Garzo Saria; Santosh Kesari
Journal:  J Neurooncol       Date:  2011-08-28       Impact factor: 4.130

4.  Leptomeningeal carcinomatosis after major remission to taxane-based front-line therapy in patients with advanced breast cancer.

Authors:  Christos Kosmas; Nikolaos A Malamos; Nicolas B Tsavaris; Melina Stamataki; Stefanos Stefanou; Achilleas Gregoriou; Sofia Rokana; Maria Vartholomeou; Minas J Antonopoulos
Journal:  J Neurooncol       Date:  2002-02       Impact factor: 4.130

5.  Sensitive detection of tumour cells in effusions by combining cytology and fluorescence in situ hybridisation (FISH).

Authors:  M Fiegl; A Massoner; M Haun; W Sturm; H Kaufmann; R Hack; J Krugmann; M Fritzer-Szekeres; K Grünewald; G Gastl
Journal:  Br J Cancer       Date:  2004-08-02       Impact factor: 7.640

Review 6.  Leptomeningeal disease: current diagnostic and therapeutic strategies.

Authors:  Gautam Nayar; Tiffany Ejikeme; Pakawat Chongsathidkiet; Aladine A Elsamadicy; Kimberly L Blackwell; Jeffrey M Clarke; Shivanand P Lad; Peter E Fecci
Journal:  Oncotarget       Date:  2017-08-16
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.